» Articles » PMID: 36978172

'Triple Clear': a Systematic and Comprehensive Surgical Process for Campanacci Grades II and III Giant Cell Tumors of the Bone, with or Without Pathological Fracture and Slight Joint Invasion

Overview
Publisher Biomed Central
Date 2023 Mar 28
PMID 36978172
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In recent years, researchers have proposed a number of adjuvant methods for extended curettage of giant cell tumors of the bone. However, various schemes have significant differences in efficacy and safety. Therefore, this article will describe an empirical expanded curettage protocol, 'triple clear', in detail to show the effect of the efficient surgical protocol.

Method: Patients with Campanacci grades II and III primary GCTB who were treated with either SR (n = 39) or TC (n = 41) were included. Various perioperative clinical indicators, including the therapy modality, operation time, Campanacci grade, and filling material were recorded and compared. The pain level was determined by the visual analog scale. Limb function was determined by the Musculoskeletal Tumour Society (MSTS) score. Follow-up time, recurrence rates, reoperation rates, and complication rates were also recorded and compared.

Result: The operation time was 135.7 ± 38.4 min in the TC group and 174.2 ± 43.0 min in the SR group (P < 0.05). The recurrence rates were 7.3% in the TC group and 8.3% in the SR group (P = 0.37). The MSTS scores at three months after surgery were 19.8 ± 1.5 in the TC group and 18.8 ± 1.3 in the SR group. The MSTS scores at two years were 26.2 ± 1.2 in the TC group and 24.3 ± 1.4 in the SR group (P < 0.05).

Conclusion: TC is recommended for patients with Campanacci grade II-III GCTB and for those with a pathological fracture or slight joint invasion. Bone grafts may be more suitable than bone cement in the long term.

Citing Articles

Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update.

Tsukamoto S, Mavrogenis A, Masunaga T, Honoki K, Fujii H, Kido A Curr Oncol. 2024; 31(4):2112-2132.

PMID: 38668060 PMC: 11048866. DOI: 10.3390/curroncol31040157.

References
1.
Seifert J, Morris D . World survey on the complications of hepatic and prostate cryotherapy. World J Surg. 1999; 23(2):109-13; discussion 113-4. DOI: 10.1007/pl00013173. View

2.
Perrin D, Visgauss J, Wilson D, Griffin A, Abdul Razak A, Ferguson P . The role of Denosumab in joint preservation for patients with giant cell tumour of bone. Bone Joint J. 2020; 103-B(1):184-191. DOI: 10.1302/0301-620X.103B1.BJJ-2020-0274.R1. View

3.
Marcove R, Lyden J, Huvos A, Bullough P . Giant-cell tumors treated by cryosurgery. A report of twenty-five cases. J Bone Joint Surg Am. 1973; 55(8):1633-44. View

4.
Nelson C, Krishnan E, Neff J . Consideration of physical parameters to predict thermal necrosis in acrylic cement implants at the site of giant cell tumors of bone. Med Phys. 1986; 13(4):462-8. DOI: 10.1118/1.595852. View

5.
Liu Q, He H, Yuan Y, Zeng H, Liu Y, Zhang C . Oncology and functional prognosis are both vital in the surgical treatment of RGCTs around the knee joint. Am J Transl Res. 2020; 12(3):1155-1165. PMC: 7137064. View